How to find and join a clinical trial for a GLP-1 or peptide drug

Search ClinicalTrials.gov, filter for recruiting studies and contact the study team; expanded access and Right to Try are the other legal routes.

Basics7 min read

Key takeaway

A drug that is not FDA-approved, such as retatrutide, can reach a patient legally only through the company developing it. That means a registered clinical trial or, for serious conditions, expanded access requested by a physician. ClinicalTrials.gov lists both. A listing is not government approval, and real trials do not ask you to pay to join.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited0
Related productsResearch peptide catalog

To find a peptide clinical trial, search ClinicalTrials.gov and contact the study team named on the record. The National Library of Medicine runs this federal registry. You cannot sign up on the site itself. This guide walks through the search, the eligibility and consent steps, what a trial costs you, and the other legal route, expanded access. It ends with the warning signs of fake "trials". Sources were checked on November 17, 2026.

Quick answer: Go to ClinicalTrials.gov. Enter the drug in the Intervention/treatment box, or your condition in the Condition/disease box. Set Study Status to recruiting and not yet recruiting studies. Open each record, read the Participation Criteria, then call or email the contact listed under Contacts and Locations. Talk with your own clinician before you decide.

Why is a trial the legal route to an unapproved drug?

An investigational drug has not finished FDA review, so no pharmacy can dispense it as an approved product. Some cannot be compounded either. FDA states that "Retatrutide and cagrilintide cannot be used in compounding under federal law" (FDA, 2026).

In a trial, the drug comes from the sponsor under a written protocol, and an ethics board reviews the study. Products sold online as research material are not trials. FDA has warned sellers of research-labeled GLP-1 products marketed to consumers for human use. For one closely watched drug, see retatrutide FDA approval and whether retatrutide is legal.

How do you search ClinicalTrials.gov step by step?

ClinicalTrials.gov's own search guide sets out these steps (ClinicalTrials.gov):

  1. Pick the right box. Type a drug name, such as semaglutide, in Intervention/treatment. Type a condition, such as obesity, in Condition/disease. Enter one term per box.
  2. Add a location. Enter your city, ZIP code or current location, then use the radius bar to set how far you can travel.
  3. Change Study Status. It starts at "All studies." Switch it to "Recruiting and not yet recruiting studies" to see trials that want participants.
  4. Narrow with More Filters. Eligibility Criteria lets you set sex, age group and whether a study accepts healthy volunteers. Study Phase lets you choose from Early Phase 1 to Phase 4.
  5. Read each record. Check the Participation Criteria section to see whether you might match.
  6. Contact the study. Use the central or site contact under Contacts and Locations. ClinicalTrials.gov itself cannot help you join a study.

Expect most results to be closed. On November 17, 2026, an Intervention/treatment search for retatrutide returned 33 records. Only 2 were recruiting or not yet recruiting.

What do the recruitment statuses mean?

Every record shows a status. Table 1 gives ClinicalTrials.gov's glossary definitions in short form.

Table 1

ClinicalTrials.gov study statuses (glossary checked November 17, 2026)

Status What it means Can you apply?
RecruitingCurrently recruiting participantsYes, if eligible
Not yet recruitingHas not started recruitingNot yet; save it and check back
Enrolling by invitationSelecting from a group chosen in advanceOnly if invited
Active, not recruitingOngoing, but not enrollingNo
Completed, terminated, withdrawn or suspendedEnded, stopped or pausedNo
Available (expanded access)Access may be possible outside the trialThrough your physician

Each study sets eligibility criteria. ClinicalTrials.gov describes inclusion criteria as requirements a person must meet and exclusion criteria as reasons a person cannot take part. Age, sex and health condition are common factors. Your clinician or the study contact can tell you whether you might qualify.

Before you join, the study team explains the study and answers your questions. This process is called informed consent. The consent form covers what will happen, who can join, the time involved, payments, costs, benefits and risks (ClinicalTrials.gov). Even after signing, you can leave the study at any time and for any reason. An institutional review board reviews studies to protect participants' rights and welfare.

Does a clinical trial cost money?

The consent form spells out payments and costs. ClinicalTrials.gov says many studies pay for the intervention and research-related tests and visits. Some cover travel costs. Participants or their insurers still pay for regular health care. Study records do not list costs, so ask the study contact.

A sponsor must get FDA's prior written authorization before charging for an investigational drug (21 CFR 312.8). The Federal Trade Commission puts it plainly: "Never pay to be part of a clinical trial" (FTC).

What is expanded access, and who can use it?

Expanded access, sometimes called compassionate use, lets a patient with a serious or life-threatening condition try an investigational drug outside a trial. FDA's conditions include these (FDA, 2026).

  • there is no comparable or satisfactory therapy, and the patient cannot get the drug through a trial;
  • the expected benefit justifies the risks;
  • a licensed physician makes the request and oversees treatment;
  • the company agrees to supply the drug, which it is not required to do;
  • an institutional review board reviews the plan, and FDA decides whether it may proceed.

Insurance often does not cover costs, and any charge must be limited to costs such as manufacturing and handling. ClinicalTrials.gov marks open expanded access programs as Available. For example, Eli Lilly lists a single-patient retatrutide program. It is limited to adults with severe obesity and serious complications who cannot join a trial (NCT07629401). FDA lists 301-796-3400 as the number physicians can call about expanded access requests for drugs (FDA, 2026).

What is Right to Try?

The federal Right to Try Act is a separate route for patients with life-threatening conditions (FDA, 2024). A physician must certify that the patient has exhausted approved options and cannot join a trial. The patient must give written informed consent. The drug must have completed a Phase 1 trial, be unapproved for any use and still be in active development. FDA states that it "does not review or approve requests for Right to Try Act use."

How can you spot a fake clinical trial?

Be wary if a "study" does any of the following:

  • Asks you to pay to join or to learn about it.
  • Asks for your Social Security number during recruitment or screening, or for bank details. The FTC warns against both.
  • Has no consent process. Real trials explain risks, costs and your right to leave before you sign.
  • Ships you a product sold as "research" material. That is a sale, not a trial; see the risks of research peptides.
  • Cannot be checked. Search its name with words such as "scam" or "complaint," as the FTC suggests, and look for its record on ClinicalTrials.gov.

A listing is a starting point, not a seal of approval. ClinicalTrials.gov states that "The U.S. government does not review or approve the safety and science of all studies listed" (ClinicalTrials.gov). Report a trial that charges people to join to the FTC. Report side effects to FDA through MedWatch, or call 1-888-INFO-FDA (1-888-463-6332) and press 2.

For the other legal routes to a peptide medicine, see how to get peptides legally and our list of FDA-approved peptide medicines.

Frequently asked questions about peptide clinical trials

How do I sign up for a retatrutide clinical trial?

Search "retatrutide" in the Intervention/treatment box on ClinicalTrials.gov and set Study Status to recruiting and not yet recruiting studies. Then contact the study team listed on a record, because you cannot sign up on the site.

How do I find a clinical trial for a peptide or GLP-1 drug?

Use ClinicalTrials.gov: enter the drug or your condition, add your location and choose recruiting studies. Check each record's Participation Criteria, then call or email the listed contact.

Can I get an unapproved drug through expanded access (compassionate use)?

Possibly, if you have a serious or life-threatening condition, no comparable treatment and no trial you can join. A licensed physician must request it, the company must agree, and FDA decides whether it may proceed.

Do I have to pay to be in a clinical trial?

Many studies pay for the study drug and research-related tests and visits, and the consent form lists any costs. The FTC advises never paying to join a trial or to find out about one.

Can I leave a clinical trial after I join?

Yes. ClinicalTrials.gov states that participants can leave a study at any time and for any reason, even after signing the consent form. Talk to the research staff so you can leave safely.

Does a listing on ClinicalTrials.gov mean the government approved the study?

No. ClinicalTrials.gov says the U.S. government does not review or approve the safety and science of all listed studies. The sponsor or investigator is responsible for each study.

What to know now

  • Where to look: ClinicalTrials.gov, filtered to recruiting and not yet recruiting studies.
  • How to join: contact the study team on the record; the site cannot enroll you.
  • Consent: you learn the risks and costs first, and you can leave at any time.
  • Costs: many studies pay for the study drug and research visits; regular care is still yours.
  • Outside a trial: expanded access needs a physician, the company and FDA; Right to Try has its own rules.
  • Red flags: fees to join, requests for your Social Security number, "research" products shipped to you.

What we're watching

New recruiting trials and expanded access listings for peptide drugs. Any FDA or FTC warnings about fake trial recruitment.

Also in the library

Sources: ClinicalTrials.gov, How to search; ClinicalTrials.gov, How to join a study; ClinicalTrials.gov, Common questions; ClinicalTrials.gov, Learn about studies; ClinicalTrials.gov, Glossary; ClinicalTrials.gov, About ClinicalTrials.gov; ClinicalTrials.gov 2026, Pre-approval expanded access of retatrutide (LY3437943); ClinicalTrials.gov 2026, Search results for the intervention retatrutide; U.S. Food and Drug Administration 2026, Expanded access: Information for patients; U.S. Food and Drug Administration 2026, Expanded access; U.S. Food and Drug Administration 2024, Right to Try; Electronic Code of Federal Regulations. 21 CFR 312.8: Charging for investigational drugs under an IND . https://www.ecfr.gov/current/title-21/section-312.8, 21 CFR 312.8: Charging for investigational drugs under an IND; Electronic Code of Federal Regulations. 21 CFR 312.305: Requirements for all expanded access uses . https://www.ecfr.gov/current/title-21/section-312.305, 21 CFR 312.305: Requirements for all expanded access uses; Federal Trade Commission 2022, COVID-19 clinical trial: real or fake? Learn how to tell the difference; U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA (MedWatch). All 16 citations

Back to the research library

References

  1. ClinicalTrials.gov, National Library of Medicine. How to search. https://clinicaltrials.gov/find-studies/how-to-search
  2. ClinicalTrials.gov, National Library of Medicine. How to join a study. https://clinicaltrials.gov/find-studies/for-patients/how-to-join
  3. ClinicalTrials.gov, National Library of Medicine. Common questions. https://clinicaltrials.gov/find-studies/for-patients/common-questions
  4. ClinicalTrials.gov, National Library of Medicine. Learn about studies. https://clinicaltrials.gov/study-basics/learn-about-studies
  5. ClinicalTrials.gov, National Library of Medicine. Glossary (recruitment status, eligibility criteria, expanded access status). https://clinicaltrials.gov/study-basics/glossary
  6. ClinicalTrials.gov, National Library of Medicine. About ClinicalTrials.gov. https://clinicaltrials.gov/about-site/about-ctg
  7. ClinicalTrials.gov. (2026). Pre-approval expanded access of retatrutide (LY3437943), NCT07629401. https://clinicaltrials.gov/study/NCT07629401
  8. ClinicalTrials.gov. (2026). Search results for the intervention retatrutide (queried November 17, 2026). https://clinicaltrials.gov/search?intr=retatrutide
  9. U.S. Food and Drug Administration. (2026). Expanded access: Information for patients (content current as of October 29, 2026). https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients
  10. U.S. Food and Drug Administration. (2026). Expanded access (content current as of October 22, 2026). https://www.fda.gov/news-events/public-health-focus/expanded-access
  11. U.S. Food and Drug Administration. (2024). Right to Try (content current as of December 12, 2024). https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try
  12. Electronic Code of Federal Regulations. 21 CFR 312.8: Charging for investigational drugs under an IND. https://www.ecfr.gov/current/title-21/section-312.8
  13. Electronic Code of Federal Regulations. 21 CFR 312.305: Requirements for all expanded access uses. https://www.ecfr.gov/current/title-21/section-312.305
  14. Federal Trade Commission. (2022). COVID-19 clinical trial: real or fake? Learn how to tell the difference. https://consumer.ftc.gov/consumer-alerts/2020/10/covid-19-clinical-trial-real-or-fake-learn-how-tell-difference
  15. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  16. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA (MedWatch). https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda